Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors

Peitao Zhang; Haixia Guan; Shukai Yuan; Huili Cheng; Jian Zheng; Zhenlei Zhang; Yifan Liu; Yang Yu; Zhaowei Meng; Xiangqian Zheng; Li Zhao

doi:10.1038/s41467-022-29000-5

Nature Communications (Mar 2022)

Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors

Peitao Zhang,
Haixia Guan,
Shukai Yuan,
Huili Cheng,
Jian Zheng,
Zhenlei Zhang,
Yifan Liu,
Yang Yu,
Zhaowei Meng,
Xiangqian Zheng,
Li Zhao

Affiliations

Peitao Zhang: The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University
Haixia Guan: Department of Endocrinology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Science
Shukai Yuan: The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University
Huili Cheng: The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University
Jian Zheng: Department of Immunology, School of Basic Medical Sciences, Tianjin Medical University
Zhenlei Zhang: The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University
Yifan Liu: The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University
Yang Yu: Department of Thyroid and Neck Oncology, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital
Zhaowei Meng: Department of Nuclear Medicine, Tianjin Medical University General Hospital
Xiangqian Zheng: Department of Thyroid and Neck Oncology, National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital
Li Zhao: The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University

DOI: https://doi.org/10.1038/s41467-022-29000-5
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 18

Abstract

Read online

BRAF-V600E mutation is common in patients with papillary thyroid carcinoma (PTC) and has been associated with an aggressive phenotype. Here the authors show that the mutation supports cancer progression by reactivating the developmental factor TBX3 and promoting the recruitment of myeloid derived suppressive cells.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal